Clinical Trial Update: A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update shows BEBT-209 in combination with chemotherapy for advanced triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• BEBT-209

Snippet

Sponsor: BeBetter Med Inc | Conditions: Advanced Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING